In Module 4, APPs will learn about insurer-mandated switching to biosimilars and how to effectively communicate with the patient. This module provides tools and resources to support patient switching, explains the nocebo effect, and reinforces health literacy and resources to support patients.
Ross M Maltz, MD
Nationwide Children’s Hospitial, Director of Very Early Onset Inflammatory Bowel Disease Program
This program made possible in part by: